Effects of Coenzyme Q10 Administration in Amyotrophic Lateral Sclerosis (ALS). Report of a Case and Review

T. Kawasaki, R. Singh, C. Germaine, F. Halberg
{"title":"Effects of Coenzyme Q10 Administration in Amyotrophic Lateral Sclerosis (ALS). Report of a Case and Review","authors":"T. Kawasaki, R. Singh, C. Germaine, F. Halberg","doi":"10.2174/1876396001205010187","DOIUrl":null,"url":null,"abstract":"Objective: Coenzyme Q10 (CoQ10) appears to be a promising agent in neurodegenerative disorders because they are associated with defects in the inner mitochondrial membrane and in oxidative phosphorylation. This report aims to highlight the role of CoQ10 in amyotrophic lateral sclerosis. Methods: A 75 year old medical scientist (1 st author TK) unbiased for treatment with CoQ10, volunteered for CoQ10 ad- ministration. He himself recorded his symptoms, mood, sensations, body weight, using limb Norris score, hand grip power for both hands. He received highly bioavailable CoQ10 in a dose of 500 mg twice daily initially followed by 200mg twice daily for treatment in 2005. (solubilized ubiquinol, Tishcon Corp. NY). His plasma CoQ10 level was ob- tained initially and after treatment with CoQ10. Results: He presented with weakness of left leg along with cramps in the left calf muscle with steppage gate in September 2000. He had wasting of muscles, fasciculations and exaggerated reflexes. He had rapid deterioration in hand grip power in the left hand and weakness in left lower limb followed by right limbs with inability in walking and routine activities. Treatment with ubiquinol in 2005, resulted in better hand grip power, mood and sensation within a month and in 2006, he reported that hand grip power and wasting of muscles are not progressing as rapidly as before administering CoQ10. Interpretations: Treatment with highly solubilized ubiquinol can provide benefit to patients with ALS. Further controlled trials would be necessary to confirm our findings.","PeriodicalId":89504,"journal":{"name":"The open nutraceuticals journal","volume":"5 1","pages":"187-192"},"PeriodicalIF":0.0000,"publicationDate":"2012-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The open nutraceuticals journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876396001205010187","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Objective: Coenzyme Q10 (CoQ10) appears to be a promising agent in neurodegenerative disorders because they are associated with defects in the inner mitochondrial membrane and in oxidative phosphorylation. This report aims to highlight the role of CoQ10 in amyotrophic lateral sclerosis. Methods: A 75 year old medical scientist (1 st author TK) unbiased for treatment with CoQ10, volunteered for CoQ10 ad- ministration. He himself recorded his symptoms, mood, sensations, body weight, using limb Norris score, hand grip power for both hands. He received highly bioavailable CoQ10 in a dose of 500 mg twice daily initially followed by 200mg twice daily for treatment in 2005. (solubilized ubiquinol, Tishcon Corp. NY). His plasma CoQ10 level was ob- tained initially and after treatment with CoQ10. Results: He presented with weakness of left leg along with cramps in the left calf muscle with steppage gate in September 2000. He had wasting of muscles, fasciculations and exaggerated reflexes. He had rapid deterioration in hand grip power in the left hand and weakness in left lower limb followed by right limbs with inability in walking and routine activities. Treatment with ubiquinol in 2005, resulted in better hand grip power, mood and sensation within a month and in 2006, he reported that hand grip power and wasting of muscles are not progressing as rapidly as before administering CoQ10. Interpretations: Treatment with highly solubilized ubiquinol can provide benefit to patients with ALS. Further controlled trials would be necessary to confirm our findings.
辅酶Q10对肌萎缩性侧索硬化症(ALS)的影响。个案报告及检讨
目的:辅酶Q10 (CoQ10)被认为是治疗神经退行性疾病的一种有前途的药物,因为它与线粒体内膜缺陷和氧化磷酸化有关。本报告旨在强调辅酶q10在肌萎缩性侧索硬化症中的作用。方法:一位75岁的医学科学家(第一作者TK)对辅酶q10治疗无偏见,自愿给予辅酶q10治疗。他自己记录了他的症状,情绪,感觉,体重,用肢体诺里斯评分,双手握力。他接受了高生物利用度的辅酶q10,最初剂量为500毫克,每天两次,随后在2005年接受了200毫克,每天两次的治疗。(可溶性泛醇,Tishcon Corp. NY)。在治疗初期和治疗后测定血浆辅酶q10水平。结果:患者于2000年9月以左腿无力伴左小腿肌痉挛为主要表现。他肌肉萎缩,肌肉收缩,反应过度。患者左手握持力迅速下降,左下肢无力,随后右下肢无力,不能行走和日常活动。2005年用泛醇治疗后,一个月内握力、情绪和感觉都有所改善。2006年,他报告说,握力和肌肉萎缩的进展不如服用辅酶q10之前那么快。解释:高溶解泛醇治疗可使ALS患者获益。需要进一步的对照试验来证实我们的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书